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Phosphorylation sites A B
FGF4 phosphoproteomics analysis in mESCs.
A) Fgf4-/-mESCs were treated with 10 μM SU5402 for 1 h and stimulated with FGF4 for the indicated times. ppERK1/2, AKT pS473, GSK3B pS9 and tubulin levels were determined by immunoblotting. B) Venn diagrams showing the overlap between the phosphoproteomics data generated in this study and two previous large-scale phosphoproteomics datasets from FGF-stimulated ESCs. Source data are provided as a Source Data file.
Supplementary Figure 1 (Related to Fig. 1 ) 
EPHA2 is the major EPH receptor expressed in mESCs.
A) Average protein copy number per cell for EPH receptor family members in mESCs using quantitative whole-cell proteomics. Data are presented as mean ± SD (n=3) B) mRNA expression of EPH receptor family members in mESCs determined by qRT-PCR analysis. Data presented as technical replicates of a representative experiment. C) mRNA expression of Epha1 in Epha2+/+, Epha2-/-or Epha2-/-mESCs (clone C4) stably expressing EPHA2 was determined by qRT-PCR analysis. Data presented as technical replicates from a representative experiment. Source data are provided as a Source Data file. Supplementary Figure 2 Epha2-/-mESCs EPHA2 supports mESC pluripotency and restricts commitment to differentiation.
A) Epha2+/+, Epha2-/-or Epha2-/-mESCs (clone C4) stably expressing EPHA2 were cultured in LIF/FBS for 48 h. EPHA2, KLF4, DNMT3B, NANOG and OCT4 levels determined by immunoblotting. B) Epha2+/+, Epha2-/-or Epha2-/-mESCs (clone C4) stably expressing EPHA2 were cultured in LIF/FBS and cells counted to determine doubling time. Data are represented as mean ± SEM (n=3). C) Epha2+/+, Epha2-/-or Epha2-/-mESCs (clone C4) stably expressing EPHA2 were cultured in LIF/FBS for 4 days. Viable cells were determined daily by MTS assay. Data are represented as mean ± SEM (n=3). D) Clonogenicity/density of alkaline phosphatase positive colonies was determined for Epha2+/+ or Epha2-/-mESCs (clone C4) in 2i or following 4 days differentiation in N2B27 media. Data show mean ± SEM (n=3). E) Epha2+/+ or Epha2-/-mESCs (clone C4) stably expressing EFNA1 were cultured for three days in N2B27 and replated in standard LIF/FBS medium for 24 h. Alkaline phosphatase activity was determined and bright field pictures taken; Scale bar, 100 μ m. F) Wild-type mESCs were differentiated as embryoid bodies for 10 days and levels of Nanog, Klf4, Oct4 and Dnmt3b mRNA determined by qRT-PCR. Data are presented as mean of technical replicates from a representative experiment. G) Epha2+/+ or Epha2-/-mESCs (clone C4) cultured in 2i were differentiated in N2B27 media for 4 days and levels of Nanog, Klf4, Oct4 and Dnmt3b, Sox1, Nestin, Kif1a and Brachyury mRNA determined by qRT-PCR. Box and whisker plots show median, first and third quartiles, and maximum and minimum values of two technical and three biological replicates (n=3). Statistical significance was determined using multiple unpaired t-tests comparing each group to control, using Holm-Sidak correction with alpha = 0.05 (Sox1 *P = 0.013999, Nestin (0 days) **P = 0.001228, Nestin (4 days) **P = 0.001450, Brachyury *P = 0.014190) H) Epha2-/-clone C4 was cultured in the absence of LIF and treated with 1 or 3 μM PD0325901 (MEK1/2i) for 48 h. KLF4, DNMT3B, NANOG, ppERK1/2 and ERK1/2 levels were determined by immunoblotting. Source data are provided as a Source Data file. 
Supplementary Figure 3 (Continued)

EPHA2 inhibitory phosphorylation and transcriptional suppression during mESC differentiation.
A) Epha2-/-mESCs were transfected with either empty vector or increasing amounts of EPHA2 and stimulated with 1 μg/ml clustered EFNA1 for 15 min. EPHA2 was immunoprecipitated and pTyr and EPHA2 levels determined by immunoblotting. B) Epha2-/-mESCs were transfected with either empty vector or indicated EPHA2 expression vectors and stimulated with 1 μg/ml clustered EFNA1 for 15 min. EPHA2 was immunoprecipitated and pTyr and EPHA2 levels determined by immunoblotting. C) Epha2+/+ mESCs were differentiated as embryoid bodies (EBs) for 10 days in the presence of vehicle control, 1 μM PD0325901 or AZD4547, and levels of Fgf5 (top) and Brachyury (bottom) mRNA determined by qRT-PCR. Fold change in mRNA expression compared to control is presented as mean ± SD (n=4). statistical significance was determined using unpaired two-sided Student's t-test comparing each group to the control (Fgf5 **P = 0.019, ****P < 0.0001, Brachyury **P = 0.0027, *P = 0.0211) D) EPH receptor mRNA expression was determined by qRT-PCR in mESCs or EBs differentiated for 6 days. Fold change of expression between EBs and mESCs is presented from two independent experiments. E) Fgf4-/-mESCs were differentiated in the presence FGF4 for the indicated times, and EPHA2, OCT4, ERK1/2 and CDH1 levels determined by immunoblotting. F) 2i mESCs were differentiated in N2B27 medium for the indicated times and EPHA2, OCT4, and CDH1 levels were determined by immunoblotting. G) 2i mESCs were treated with 2 μM of the indicated inhibitors and differentiated in N2B27 medium for 3 days. EPHA2, NANOG, ERK1/2 and tubulin levels were determined by immunoblotting. Source data are provided as a Source Data file.
Supplementary Figure 4 
OCT4 controls EPHA2 expression in mESCs.
A) Wild-type mESCs were transfected with the indicated siRNAs and NANOG, DNMT3B and OCT4 levels determined by immunoblotting. (*) = non-specific band. B) Wild-type mESCs were transfected with the indicated siRNAs for 24h and EPHA2, OCT4, NANOG, SOX2 and ERK1/2 levels determined by immunoblotting. C) Wild-type mESCs were treated with JQ1 for the indicated time and concentration and EPHA2, NANOG, OCT4 and ERK1/2 levels determined by immunoblotting. D) Wild-type mESCs were transfected with the indicated siRNAs and EPHA2, OCT4, NANOG, SOX2 and ERK1/2 levels determined by immunoblotting. E) Epha2+/+ and Epha2-/-mESCs were fixed, immunostained for EPHA2 and nucleus counterstained for DAPI. 
E5.5 Epiblast
EPH receptor expression during a time-course of early mouse embryonic development
Data corresponding to EPH receptor mRNA expression was extracted from Table S1 Epha2 exon 3
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Generation of CRISPR/Cas9 Epha2-/-cell lines
A) Epha2-/-mESCs were generated using CRISPR/Cas9 D10A and the indicated sense and antisense gRNA sequences as described in experimental procedures. Genomic and predicted protein sequences of 3 independent Epha2-/-clones were determined. B) Schematic of the predicted Epha2 gene and protein in Epha2-/-clones. C) Immunoblot analysis of EPHA2 expression using N-terminal and C-terminal specific antibodies in control wild-type mESCs and prospective Epha2-/-mESC clones. mESC lines that were selected for further analysis and experiments are indicated. Epha2 CRISPR/Cas9 knockin strategy A) CRISPR/Cas9 method was used to introduce 5 point mutations in the C-terminal region of EPHA2. B) Paired CRISPR/Cas9 guide RNAs were designed to target exon 16 of the Epha2 gene in order to replace endogenous EPHA2 with either EPHA2 WT or EPHA2 5A mutant. Genomic PCR (C) and DNA sequencing (D) of Epha2 WT-KI and 5A-KI mESCs confirmed the presence of wild-type or introduction of the 5A-KI donor. In the case of the WT KI, only one allele was targeted by the donor arm and therefore three bands are shown in the gel. Sequencing revealed a 45 bp deletion in the upstream intron 15-16, which does not affect protein expression or function. Supplementary Figure 9 : Full-size blot scans 
Supplementary methods
Phosphoproteomic profiling
Cell culture and proteomic sample preparation: Fgf4-/-mESCs were cultured in LIF/FBS then starved for 4 h before stimulation with 100 ng/ml FGF4 (Peprotech). Cell pellets were lysed with 1 ml of lysis buffer (8 M Urea, 50 mM Ammonium bicarbonate containing protease inhibitor and phosphatase inhibitor). Samples were left on ice for 15 min and sonicated for 5 min at high intensity (30 sec on and off) in ice-cold water bath. After sonication, benzonase® endonuclease (Merck Millipore) was added to the lysate (1:100) to degrade DNA and RNA 1 . The lysates were then centrifuged at 12,000 rpm for 15 min at 4 °C, and supernatants were transferred into new eppendorf tubes. Protein concentrations were measured by BCA assay (Pierce™ BCA Protein Assay Kit, Thermo). A total of 7.5 mg protein from each sample was reduced with 5 mM DTT at 45 °C for 30 min. Lysates were briefly centrifuged and cooled to room temperature before alkylation in the dark with 10 mM iodoacetamide at room temperature. The alkylation was quenched by the addition of 5 mM DTT. Samples were first digested by Lys-C at weight ratio of 1:200 (w/w) for 4 h at 30 °c. Samples were then diluted with 50 mM ammonium bicarbonate to 1.5 M Urea concentration, followed by trypsin (Pierce trypsin, Thermo) at an enzyme to protein ratio of 1:50 (w/w) at room temperature with gentle shaking for overnight. The digest was stopped by the addition of 1% (v/v) TFA, and samples centrifuged at 10,000 g for 10 min at room temperature. Supernatants were desalted on 200 mg SepPak tC18 cartridge (Waters), and desalted peptides dried by vacuum centrifugation using Speedvac (Thermo).
Phosphopeptide Enrichment and TMT labelling: All samples were enriched for phosphopeptides using a TiO 2 microspheres (Titansphere® TiO 5 µM, GL Science) according to [2] [3] [4] . In brief, TiO 2 microspheres were equilibrated with 50 % ACN/ 2 M lactic acid (binding buffer) twice. 5 mg of desalted sample was 20 dissolved in 1 ml of binding buffer and incubated with 1 mg of TiO 2 microspheres with high speed shaking (1400 rpm) for 1 h at room temperature. TiO 2 microspheres were then washed twice with 1 ml binding buffer and three times with 1 ml of 50% ACN/0.1% TFA. with a 1% FDR using Percolator.
The phosphoRS 6 node was used to localize phosphorylation sites with a probability at least 90% to be considered as confident. Both unique and razor peptides were used for quantitation.
Reporter ion abundances were corrected for isotopic impurities based on the manufacturer's data sheets. Signal-to-noise (S/N) values were used to represent the reporter ion abundance with a coisolation threshold of 50% and an average reporter S/N threshold of 10 and above required for quantitation from each MS2 spectra to be used. The S/N value of each reporter ion from each PSM were used to represent the abundance of the localised phosphorylation sites. The precursor spectra with higher than 25% co-isolation were checked manually. The median was used for the normalisation and quantification calculated as average of three biological replicates, with standard deviation of three biological replicates lower than 25% used for further analyses. 
Quantitative total cell proteomics
